Neuro-Hitech, Inc. (OTCMKTS:WDBG) is a biotechnology company specializing in the development and commercialization of treatments for neurodegenerative diseases. The company’s core focus lies in small‐molecule therapies designed to slow or halt the progression of disorders such as Parkinson’s disease, Alzheimer’s disease and multiple system atrophy. Leveraging proprietary screening platforms and in-house medicinal chemistry capabilities, Neuro-Hitech aims to identify novel compounds that address underlying biological pathways implicated in neuronal damage and protein aggregation.
Neuro-Hitech’s product pipeline includes lead candidate NH-1101, a molecule targeting alpha-synuclein aggregation in Parkinson’s patients, and NH-1202, which is being investigated for efficacy in early‐stage Alzheimer’s. Both candidates have completed preclinical toxicology and pharmacokinetic studies, and the company is preparing for Phase I clinical trials. In addition to its therapeutic programs, Neuro-Hitech offers contract research services in neuropharmacology and assay development, supporting external partners in validating small‐molecule leads against central nervous system targets.
Founded in 2014 and headquartered in Dallas, Texas, Neuro-Hitech operates a research facility on the University Park campus and maintains a subsidiary in Basel, Switzerland, to facilitate European collaboration and regulatory filings. The leadership team is headed by CEO Dr. Emily Carter, a neuroscientist with over 20 years of experience in neurology R&D, and CFO Robert Lin, who oversees financial strategy and investor relations. The company’s scientific advisory board features prominent neurologists and pharmacologists from major academic centers, supporting its mission to bring innovative neurotherapeutics to market.
AI Generated. May Contain Errors.
